July 09, 2026 Fulgent Genetics Inc. to Release Second Quarter Financial Results on July 30, 2026 Fulgent Genetics is set to announce its second quarter financial results for 2026 on July 30. Investors can join a conference call to gain insights into the company's performance and strategic initiatives in the biotech sector.
June 01, 2026 Fulgent Genetics Unveils Promising FID-007 Data at ASCO 2026 At ASCO 2026, Fulgent Genetics shared promising data on FID-007 for treating recurrent or metastatic head and neck squamous cell carcinoma. The combination with cetuximab showed a 61.9% response rate, indicating a hopeful advancement in cancer treatment options.
May 21, 2026 Fulgent Genetics Inc. Announces Promising Results for FID-007 in Head and Neck Cancer Fulgent Genetics announced promising interim results for FID-007 in a Phase 2 trial for head and neck cancer, showing a 60% objective response rate. The drug's favorable safety profile and potential effectiveness against current treatments highlight its significance in oncology.
May 01, 2026 Fulgent Genetics Inc. Reports First Quarter 2026 Financial Results Fulgent Genetics reported a revenue of $71.1 million in Q1 2026 but faced a GAAP loss of $24.8 million. The results highlight operational challenges and the need for strategic adjustments as the company navigates a competitive biotechnology landscape.
May 01, 2026 Fulgent Genetics Inc. Reports Q1 2026 Results: A Mixed Bag Following Strategic Acquisition Fulgent Genetics Inc. faced a challenging Q1 2026, reporting a 3% revenue decline and a significant net loss. The recent acquisition of Bako Diagnostics is seen as a strategic move for future growth despite current operational pressures.
April 22, 2026 Fulgent Genetics to Present Promising Head and Neck Cancer Data at ASCO 2026 Fulgent Genetics is set to present its Phase 2 study results for FID-007, a new treatment for recurrent head and neck cancer, at ASCO 2026. The presentation, featuring interim data and insights into its efficacy, will take place on June 1, 2026, in Chicago, highlighting a potential breakthrough in cancer therapy.
March 25, 2026 Fulgent Genetics Faces Scrutiny Amidst Stock Plunge and Investigation Fulgent Genetics Inc. is under investigation by Kirby McInerney LLP following a 38% drop in its stock price due to disappointing financial results. The investigation focuses on potential securities law violations and the adequacy of the company's disclosures, with impacted investors encouraged to seek legal advice.
March 17, 2026 Fulgent Genetics Inc. Under Investigation for Potential Securities Fraud Fulgent Genetics Inc. is facing a securities fraud investigation by Kirby McInerney LLP after reporting disappointing financial results, leading to a sharp stock decline. Investors are urged to remain vigilant as the investigation unfolds.
March 17, 2026 Fulgent Genetics Expands Portfolio with Strategic Acquisitions Fulgent Genetics has acquired Bako Diagnostics and StrataDx for $56.9 million, aiming to transform into a fully integrated precision medicine company. These acquisitions enhance its laboratory services, particularly in pathology and dermatopathology, positioning Fulgent for future growth and innovation.
February 27, 2026 Fulgent Genetics Reports Fourth Quarter and Full Year 2025 Financial Results Fulgent Genetics reported a 9% revenue growth in Q4 2025 despite posting a GAAP loss of $23.4 million. For the full year, revenue reached $322.7 million, highlighting the company’s resilience amid financial challenges. The article explores the contrast between GAAP and non-GAAP results and the company’s strategic outlook.
February 27, 2026 Fulgent Genetics Inc. Reports 2025 Annual Results: Navigating Challenges and Seizing Opportunities Fulgent Genetics Inc. reported a revenue increase to $322.7 million in 2025, despite facing operational losses and challenges from customer transitions. The company made significant acquisitions and investments while navigating a complex market landscape.
February 12, 2026 Fulgent Genetics Set to Release Fourth Quarter and Full Year 2025 Financial Results Fulgent Genetics is set to release its financial results for Q4 and full year 2025 on February 27, 2026. The company will also host a conference call to discuss these results and its strategic vision in personalized medicine and cancer treatment.
December 22, 2025 Fulgent Genetics Expands Laboratory Services with Strategic Acquisitions of Bako Diagnostics and StrataDx Fulgent Genetics has announced the acquisition of Bako Diagnostics and StrataDx for $55.5 million to enhance its laboratory services and pathology testing capabilities. This strategic move aims to expand Fulgent's diagnostic offerings and geographic reach, integrating advanced technologies and expertise.
November 07, 2025 Fulgent Genetics Inc. Gears Up for Key Investor Conferences Fulgent Genetics is set to present at two major investor conferences in November and December 2025, emphasizing its advancements in genomic diagnostics and cancer therapies. The company aims to engage investors and showcase its strategic vision for precision medicine through live webcasts and in-person presentations.
November 07, 2025 Fulgent Genetics Reports Strong Revenue Growth Amid Mixed Financial Results for Q3 2025 Fulgent Genetics achieved a 17% revenue growth in Q3 2025, totaling $84.1 million, while reporting a GAAP loss of $6.6 million. The company's strategic focus on expanding laboratory services is promising, but ongoing profitability concerns remain as it navigates operational challenges.
November 07, 2025 Fulgent Genetics Inc. Reports Strong Q3 2025 Results Amidst Operational Challenges Fulgent Genetics Inc. has reported a 17% revenue growth for Q3 2025, reaching $84.1 million, driven by advancements in precision diagnostics. Despite a net loss of $6.6 million, the company maintains a strong liquidity position and continues to invest in its growth strategy amidst operational challenges.
October 20, 2025 Fulgent Genetics Unveils Promising Preliminary Data for FID-007 at ESMO 2025 Conference Fulgent Genetics unveiled promising preliminary results of FID-007 combined with cetuximab at ESMO 2025, showing a 51% overall response rate in head and neck cancer. The therapy demonstrated significant progression-free survival and a favorable safety profile, highlighting its potential in cancer treatment.
October 16, 2025 Fulgent Genetics Set to Reveal Q3 2025 Financial Results Fulgent Genetics is set to release its Q3 2025 financial results on November 7, 2025, along with a conference call for investors. This announcement highlights the company's commitment to transparency and its ongoing innovation in biotechnology and cancer treatment.
August 01, 2025 Fulgent Genetics Inc. Reports Robust Q2 2025 Earnings Amidst Strategic Growth Fulgent Genetics Inc. reported a 15% revenue growth in Q2 2025, driven by laboratory services and precision diagnostics. Despite a net loss of $18.95 million, strong liquidity and strategic focus on growth position the company favorably in the healthcare sector.
May 02, 2025 Fulgent Genetics Inc. Reports First Quarter 2025 Financial Results Fulgent Genetics reported a 16% increase in core revenue to $73.5 million in Q1 2025, despite a GAAP loss of $11.5 million. The company is focusing on expanding its lab services and managing costs as it aims for sustainable profitability.
May 02, 2025 Fulgent Genetics Inc. Reports Strong Q1 2025 Results Amid Strategic Shifts Fulgent Genetics Inc. reported a 14% revenue increase to $73.5 million in Q1 2025, driven by precision diagnostics and therapeutic development. Despite a net loss, the company shows strong liquidity and commitment to future growth in the healthcare market.
April 10, 2025 Fulgent Genetics Set to Release Q1 2025 Financial Results Fulgent Genetics will release its Q1 2025 financial results on May 2, 2025, before market opening, followed by a conference call at 8:30 AM ET. The company emphasizes transparency in its operations and seeks to highlight its growth in laboratory services and therapeutic development.
February 28, 2025 Fulgent Genetics Releases 2024 Financial Results: A Mixed Bag of Growth and Losses Fulgent Genetics reported a 14% revenue increase in Q4 2024, reaching $76.2 million, despite a GAAP loss of $5.9 million. The company's full-year revenue stood at $283.5 million with ongoing operational challenges. Strong cash reserves provide avenues for future growth.
February 28, 2025 Fulgent Genetics Inc. Reports 2024 Annual Results: Navigating Challenges Amidst Growth Fulgent Genetics Inc. reported a 2% decline in revenue in 2024, primarily due to reduced demand for COVID-19 testing, but made significant strides in therapeutic development. The company's focus on innovative cancer treatments and strategic management of costs positions it for future growth.
February 06, 2025 Fulgent Genetics Inc. Set to Release Q4 and Full Year 2024 Financial Results Fulgent Genetics, Inc. will release its financial results for Q4 and the full year of 2024 on February 28, 2025. A conference call will follow to discuss the results and engage with investors. The company is recognized for its innovative laboratory services and therapeutic development in precision medicine.
January 27, 2025 SWOT Analysis of Fulgent Genetics Inc. in 2025 This article presents a SWOT analysis of Fulgent Genetics Inc. in 2025, detailing its technological strengths, market challenges, and opportunities for growth in precision medicine. The analysis highlights the company’s commitment to innovation amid competitive pressures and regulatory complexities.
November 08, 2024 Fulgent Genetics Inc.: Q3 2024 Financial Report Analysis Fulgent Genetics Inc. reported a 15% decline in Q3 2024 revenue, primarily due to reduced COVID-19 testing demand. Despite challenges, the company increased its R&D investments significantly, aiming to innovate in therapeutic development. The balance sheet remains robust, positioning Fulgent for potential recovery.
August 02, 2024 Fulgent Genetics Inc. Reports Q2 2024 Financial Results: A Mixed Bag of Growth and Challenges Fulgent Genetics Inc. reported a 5% revenue increase in Q2 2024, driven by precision diagnostics. Despite cost reductions, the company faced an operating loss of $18.90 million. Future investments in R&D highlight its commitment to oncology innovation.
May 03, 2024 Fulgent Genetics Inc. Reports 2024 Q1 Financial Results: A Mixed Bag Amid Transition Fulgent Genetics Inc. reported a 3% revenue decline in Q1 2024, driven by reduced demand in COVID-19 testing and BioPharma services. Despite a net loss, cost management efforts led to improved cash flow and a strong liquidity position, supporting their transition towards precision diagnostics.
